Bio-Techne Corporation(TECH)Earnings, Financials & Key RatiosBio-Techne Corporation (TECH) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q3
while the company demonstrates strong cash conversion with a 24.9% FCF margin, the current 154.35 P/E ratio suggests the stock is priced for growth that is not currently reflected in the recent 1.5% revenue decline.
Bio-Techne Corporation (TECH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Bio-Techne Corporation (TECH) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.53vs $0.55-3.6% | $311Mvs $316M-1.5% |
| Q1 2026 | Feb 4, 2026 | $0.46vs $0.43+7.0% | $296Mvs $290M+1.9% |
| Q4 2025 | Nov 5, 2025 | $0.42vs $0.42-0.3% | $287Mvs $291M-1.6% |
| Q3 2025 | Aug 6, 2025 | $0.53vs $0.50+6.1% | $317Mvs $295M+7.6% |
Recent stock market news and headlines for Bio-Techne Corporation (TECH)
ANTWERP, Belgium, 29 June 2026, 08:00 CET – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) has sold two Suezmaxes, generating a capital gain of approximately 100.5 million USD.
Bio-Techne Corporation (TECH) M&A Call Transcript
On June 25, 2026, investors tracked deal progress as Bio-Techne shares responded to the proposed buyout terms.
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026
Key metrics vs top competitors for Bio-Techne Corporation (TECH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $71.00 | $11.12B | 154.35 | 5.23% | 6.02% | 3.68% | 0.44% | |
| $139.83 | $7.89B | 162.59 | 16.36% | 6.73% | 2.46% | — | |
| $9.39 | $2.04B | -1.87 | -3.2% | -69.93% | -29% | — | |
| $25.37 | $1.17B | -20.80 | 3.55% | -29.86% | -10.69% | — | |
| $112.05 | $12.53B | 53.87 | 3.67% | 8.3% | 3.28% | — | |
| $14.29 | $1.84B | -17.01 | 191.39% | -593.92% | -17.1% | — |
Bio-Techne Corporation (TECH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Bio-Techne Corporation (TECH) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 6, 2026·SEC
Feb 11, 2026·SEC
Feb 4, 2026·SEC
Get notified when TECH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Bio-Techne Corporation (TECH) stock FAQ — growth, dividends, profitability & financials explained
Bio-Techne Corporation (TECH) reported $1.21B in revenue for fiscal year 2025. This represents a 2118% increase from $54.6M in 1996.
Bio-Techne Corporation (TECH) grew revenue by 5.2% over the past year. This is steady growth.
Yes, Bio-Techne Corporation (TECH) is profitable, generating $109.6M in net income for fiscal year 2025 (6.0% net margin).
Yes, Bio-Techne Corporation (TECH) pays a dividend with a yield of 0.44%. This makes it attractive for income-focused investors.
Bio-Techne Corporation (TECH) has a return on equity (ROE) of 3.7%. This is below average, suggesting room for improvement.
Bio-Techne Corporation (TECH) generated $269.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
